Scientific Plenary VI: Immunotherapy: Treatment, Trials, Toxicity

Scientific Plenary


  • Marilyn Huang, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami Beach, FL
  • Alessandro Santin, MD, Yale University School Of Medicine, New Haven, CT


  • Gini Fleming, MD, University of Chicago Medical Center, Chicago, IL


  • Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute, Buffalo, NY

Description: Recent years have seen remarkable success in immunotherapy of cancer. The goal of this course is to provide a brief overview of the clinical efficacy and toxicity of various cancer immunotherapy agents with a particular emphasis on the results of recent clinical trials using cell-based immunotherapies and immune check point inhibitors in gynecologic tumors.

Location: Kamehameha 3

Phase II trial of pembrolizumab with cisplatin and gemcitabine in women with recurrent platinum-resistant ovarian cancer

C. Walsh, M. Kamrava, A. Rogatko, A.J. Li, I. Cass, B.Y. Karlan and B.J. Rimel
Cedars-Sinai Medical Center, Los Angeles, CA, USA

Preliminary safety, efficacy, and pharmacokinetic/pharmacodynamic characterization from GARNET, a phase I/II clinical trial of the anti–PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-h and MSS endometrial cancer

A. Oaknin1, L.R. Duska2, R.J. Sullivan3, B. Pothuri4, S.L. Ellard5, C.A. Leath III6, V. Moreno7, R.S. Kristeleit8, W. Guo9, H. Danaee9, E. Im9 and L. Gilbert10
1Vall d’Hebrón University Hospital, Vall d’Hebrón Institute of Oncology (VHIO), Barcelona, Spain, 2Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville, VA, USA, 3Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 4New York University, New York, NY, USA, 5British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada, 6University of Alabama at Birmingham, Birmingham, AL, USA, 7START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain, 8University
College London UCL Cancer Institute, London, United Kingdom, 9TESARO, Inc., Waltham, MA, USA, 10McGill University, McGill University Health Centre, Montreal, QC, Canada

A phase II study of atezolizumab in combination with bevacizumab in patients with recurrent, persistent or metastatic cervical cancer

C.F. Friedman1, A. Snyder1, E. Sharon2, A. Buckley De Meritens3, L.A. Cantrell4, B.R. Corr5,6, J. Konner1, P.A. Konstantinopoulos7, K. Soldan1, C.A. Aghajanian1,8 and D. Zamarin1
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2CTEP, National Cancer Institute, Bethesda, MD, USA, 3University of Medicine and Dentistry of New Jersey (UMDNJ)-The Cancer Institute of New Jersey, New Brunswick, NJ, USA, 4University of Virginia, Charlottesville, VA, USA, 5University of Colorado School of
Medicine, Aurora, CO, USA, 6University of Colorado Denver, Aurora, CO, USA, 7Dana-Farber Cancer Institute, Boston, MA, USA, 8Weill Cornell Medical College, New York, NY, USA

Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02)

D. Cibula1, L. Rob2, P. Mallmann3, P. Knapp4, J. Bartunkova5, R. Spisek6, H.I.B. Hassan6, L. Pecen7, J. Klat8 and J. Chovanec9
1Charles University and General Faculty Hospital, Prague, Czech Republic, 2University Hospital Kralovske Vinohrady, Prague, Czech Republic, 3University Hospital of Cologne, Cologne, Germany, 4Medical University of Bialystok, Bialystok, Poland, 5University Hospital Motol, Prague, Czech Republic, 6SOTIO a.s., Prague, Czech
Republic, 7Institute of Computer Science, Academy of Sciences of the Czech Republic, Prague, Czech Republic, 8University Hospital Ostrava, Ostrava, Czech Republic, 9Masaryk Memorial Cancer Institute, Brno, Czech Republic